R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia.
Tonino
S H
SH
van Gelder
M
M
Eldering
E
E
van Oers
M H
MH
Kater
A P
AP
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D016159:Tumor Suppressor Protein p53 / Q000502:physiology; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D016159:Tumor Suppressor Protein p53; D003561:Cytarabine; D000069283:Rituximab; D003907:Dexamethasone; D014740:Vidarabine; C024352:fludarabine; D002945:Cisplatin